Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study.
Aldosterone-to-renin ratio
Diabetes
Hypertension
Primary aldosteronism
Renin-angiotensin-aldosterone system
SGLT2 inhibitor
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
30 Nov 2020
30 Nov 2020
Historique:
received:
28
06
2020
accepted:
20
11
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
29
9
2021
Statut:
epublish
Résumé
Plasma aldosterone-to-renin ratio (ARR) is popularly used for screening primary aldosteronism (PA). Some medications, including diuretics, are known to have an effect on ARR and cause false-negative and false-positive results in PA screening. Currently, there are no studies on the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are known to have diuretic effects, on ARR. We aimed to investigate the effects of SGLT2 inhibitors on ARR. We employed a retrospective design; the study was conducted from April 2016 to December 2018 and carried out in three hospitals. Forty patients with diabetes and hypertension were administered SGLT2 inhibitors. ARR was evaluated before 2 to 6 months after the administration of SGLT2 inhibitors to determine their effects on ARR. No significant changes in the levels of ARR (90.9 ± 51.6 vs. 81.4 ± 62.9) were found. Body mass index, diastolic blood pressure, heart rate, fasting plasma glucose, and hemoglobin A1c were significantly decreased by SGLT2 inhibitors. Serum creatinine was significantly increased. SGLT2 inhibitor administration yielded minimal effects on ARR and did not increase false-negative results in PA screening in patients with diabetes and hypertension more than 2 months after administration.
Sections du résumé
BACKGROUND
BACKGROUND
Plasma aldosterone-to-renin ratio (ARR) is popularly used for screening primary aldosteronism (PA). Some medications, including diuretics, are known to have an effect on ARR and cause false-negative and false-positive results in PA screening. Currently, there are no studies on the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are known to have diuretic effects, on ARR. We aimed to investigate the effects of SGLT2 inhibitors on ARR.
METHODS
METHODS
We employed a retrospective design; the study was conducted from April 2016 to December 2018 and carried out in three hospitals. Forty patients with diabetes and hypertension were administered SGLT2 inhibitors. ARR was evaluated before 2 to 6 months after the administration of SGLT2 inhibitors to determine their effects on ARR.
RESULTS
RESULTS
No significant changes in the levels of ARR (90.9 ± 51.6 vs. 81.4 ± 62.9) were found. Body mass index, diastolic blood pressure, heart rate, fasting plasma glucose, and hemoglobin A1c were significantly decreased by SGLT2 inhibitors. Serum creatinine was significantly increased.
CONCLUSION
CONCLUSIONS
SGLT2 inhibitor administration yielded minimal effects on ARR and did not increase false-negative results in PA screening in patients with diabetes and hypertension more than 2 months after administration.
Identifiants
pubmed: 33256676
doi: 10.1186/s12902-020-00656-8
pii: 10.1186/s12902-020-00656-8
pmc: PMC7706199
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Aldosterone
4964P6T9RB
Renin
EC 3.4.23.15
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
177Références
Diabetes. 2005 Dec;54(12):3427-34
pubmed: 16306358
Diabetes Obes Metab. 2014 Nov;16(11):1087-95
pubmed: 24939043
Adv Ther. 2017 Feb;34(2):436-451
pubmed: 27981497
PLoS One. 2016 Nov 1;11(11):e0165703
pubmed: 27802313
Circulation. 1977 Nov;56(5):691-8
pubmed: 912827
Clin Exp Hypertens. 2018;40(2):118-125
pubmed: 28723305
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
J Renin Angiotensin Aldosterone Syst. 2001 Sep;2(3):156-69
pubmed: 11881117
Diabetes Care. 2007 Jul;30(7):1699-703
pubmed: 17429062
Endocr J. 2013;60(8):967-76
pubmed: 23719847
Horm Metab Res. 2010 Jun;42(6):435-9
pubmed: 20119885
J Hypertens. 2017 Oct;35(10):2059-2068
pubmed: 28598954
Eur J Endocrinol. 2012 Dec 10;168(1):75-81
pubmed: 23033260
Clin Chem. 2004 Sep;50(9):1650-5
pubmed: 15247156
Horm Metab Res. 2017 Jan;49(1):5-9
pubmed: 27300475
Am J Hypertens. 2018 Apr 13;31(5):522-531
pubmed: 29534182
Clin Endocrinol (Oxf). 2002 Oct;57(4):457-65
pubmed: 12354127
Int J Cardiol. 2015 Dec 15;201:1-3
pubmed: 26278671
Diabetes. 2012 Sep;61(9):2199-204
pubmed: 22923645
Curr Hypertens Rep. 2003 Apr;5(2):106-9
pubmed: 12642008
Diabetes Care. 2017 Jun;40(6):771-776
pubmed: 28325783
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Cardiovasc Diabetol. 2019 Apr 5;18(1):46
pubmed: 30953516
Hypertension. 2008 Jun;51(6):1403-19
pubmed: 18391085
Int J Mol Sci. 2019 Feb 01;20(3):
pubmed: 30717173
Hypertension. 2002 Dec;40(6):897-902
pubmed: 12468576
Arch Intern Med. 2008 Jan 14;168(1):80-5
pubmed: 18195199
Endocr J. 2011;58(9):711-21
pubmed: 21828936
Nat Rev Endocrinol. 2012 Feb 07;8(8):495-502
pubmed: 22310849
Adv Ther. 2015 Aug;32(8):768-82
pubmed: 26280756
Am J Med Sci. 2013 Jun;345(6):497-500
pubmed: 23313950
Clin Chem. 2005 Feb;51(2):386-94
pubmed: 15681560
Diabetes Obes Metab. 2013 Sep;15(9):853-62
pubmed: 23668478
Endocr J. 2018 Aug 27;65(8):859-867
pubmed: 29806620
J Mol Endocrinol. 2011 Jan 19;46(1):37-49
pubmed: 21106862
Circ J. 2016 Oct 25;80(11):2277-2281
pubmed: 27599528
Hypertens Res. 2016 Mar;39(3):133-7
pubmed: 26606875
Front Endocrinol (Lausanne). 2018 Jul 26;9:421
pubmed: 30093883
J Am Heart Assoc. 2017 May 25;6(6):
pubmed: 28546454
J Am Coll Cardiol. 2005 Apr 19;45(8):1243-8
pubmed: 15837256
J Clin Endocrinol Metab. 2006 Sep;91(9):3457-63
pubmed: 16822818
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175